Provided by Tiger Trade Technology Pte. Ltd.

RenovoRx Inc

0.8830
+0.01802.08%
Post-market: 0.8807-0.0023-0.26%19:50 EST
Volume:510.10K
Turnover:463.82K
Market Cap:32.36M
PE:-2.48
High:0.9380
Open:0.9200
Low:0.8651
Close:0.8650
52wk High:1.45
52wk Low:0.7006
Shares:36.65M
Float Shares:30.09M
Volume Ratio:3.82
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3554
EPS(LYR):-0.3958
ROE:-146.61%
ROA:-68.39%
PB:4.01
PE(LYR):-2.23

Loading ...

RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares

Reuters
·
Jan 05

RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares

Reuters
·
Jan 03

RenovoRx Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance

Reuters
·
Jan 03

RenovoRx CEO Shaun Bagai Reports Acquisition of Common Shares

Reuters
·
Dec 22, 2025

RenovoRx CEO Shaun Bagai Reports Acquisition of Common Shares

Reuters
·
Dec 19, 2025

RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares

Reuters
·
Dec 17, 2025

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

GlobeNewswire
·
Dec 11, 2025

RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares

Reuters
·
Dec 08, 2025

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

GlobeNewswire
·
Dec 01, 2025

RenovoRx CMO Makes Bold Stock Purchase

TIPRANKS
·
Nov 25, 2025

RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares

Reuters
·
Nov 25, 2025

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

GlobeNewswire
·
Nov 19, 2025

RenovoRx Showcases Cancer Therapy Advances and RenovoCath Commercialization in New Investor Presentation

Reuters
·
Nov 19, 2025

Strategic Expansion and Promising Clinical Results Justify Buy Rating for RenovoRx

TIPRANKS
·
Nov 18, 2025

RenovoRx’s Innovative Cancer Treatment and Promising Phase 3 Study Drive Buy Rating

TIPRANKS
·
Nov 16, 2025

RenovoRx Earnings Call: Positive Momentum and Strategic Growth

TIPRANKS
·
Nov 15, 2025

RenovoRx Enters Capital on Demand Sales Agreement

TIPRANKS
·
Nov 15, 2025

BRIEF-RenovoRx May Offer Securities For Up To $50 Million - SEC Filing

Reuters
·
Nov 15, 2025

RenovoRx Inc - May Offer Securities for up to $50 Mln - SEC Filing

THOMSON REUTERS
·
Nov 15, 2025

Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Forte Biosciences (FBRX)

TIPRANKS
·
Nov 15, 2025